Clinical trials: Choroidal Neovascular Membrane
Age Related Macular Degeneration, Choroidal Neovascular Membrane
A Study of Intravitreal Injections of 2.0mg Ranibizumab in Subjects With Chronic Fluid On OCT Post Multiple Injections With Ranibizumab (Super-dose Anti-VEgf SAVE Trial)
The purpose of this study is to determine whether 2.0mg Ranibizumab is effective in the treatment of recurrent fluid.
- Conditions
- Age Related Macular Degeneration, Choroidal Neovascular Membrane, Subfoveal Neovascular Age-Related Macular Degeneration, Macular Degeneration
- Trial name
- SAVE (NCT01025232)
- Testing
- Ranibizumab
- Where
- 2 sites in United States
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- David M. Brown, M.D.
Age-Related Macular Degeneration, Choroidal Neovascularization
20089 TA+Lucentis Combo Intravitreal Injections for Treatment of Neovascular Age-related Macular Degeneration (AMD)
The primary purpose of this study is to assess the safety \& tolerability of an investigational drug 20089 TA (6.9 mg or 13.8 mg) when used adjunctively with Lucentis 0.5 mg in subjects with sub-foveal neovascular AMD.
- Trial name
- 20089/Combo (NCT01175395)
- Testing
- IBI-20089/Lucentis
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of Illinois Chicago
Age-Related Macular Degeneration, Choroidal Neovascularization
Infliximab, Sirolimus and Daclizumab to Treat Age-Related Macular Degeneration
This study examined whether the anti-inflammatory medicines infliximab, sirolimus or daclizumab, when given with a participant's current therapies, would prevent the growth of new blood vessels in the eye in participants with…
- Trial name
- AMDB1 (NCT00304954)
- Testing
- Intravenous Daclizumab, Intravenous Infliximab, Observation
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- National Eye Institute (NEI)